Recalibrating intellectual property rights to enhance translational research collaborations

Authors

Tania M. Bubela, University of Alberta, CanadaFollow
Garret A. FitzGerald, University of Alberta, Canada
E Richard Gold, University of Alberta, Canada

Document Type

Commentary

Department

Office of the Provost

Abstract

Multisectoral collaborative models for drug and therapeutic research and development (R&D) are emerging, requiring a recalibration of how intellectual property rights (IPRs) are used. Although these models appear promising, little study has been conducted on the optimal blend of sharing and exclusion as mediated through the proactive use or nonuse of IPRs. This Commentary is a call for a combination of theoretical and empirical analyses to build a comprehensive understanding of the interplay between formal IP laws, institutions that administer and manage IPRs, and the use of IPRs in practice to better construct and manage collaborations. Such analyses require outcome metrics formulated to measure the success of therapeutic outcomes and to capture the complexity of a highly networked R&D environment.

Comments

Pagination are not provided by the author/publisher. This work was published before Tania joined Aga Khan University.

Publication (Name of Journal)

Science Translational Medicine

DOI

10.1126/scitranslmed.3003490

Recommended Citation

Bubela, T. M., FitzGerald, G. A., Gold, E. R. (2012). Recalibrating intellectual property rights to enhance translational research collaborations. Science Translational Medicine, 4(122), 122cm3.
Available at: https://ecommons.aku.edu/provost_office/788